NEWS
-
NEWS
Leadership Transition
Metcela announces changes in executive leadership as follows.
Read more… -
NEWS
Metcela to Strengthen Clinical Pipeline Development, New Headquarters and R&D Center at Kawasaki King Skyfront
Accelerating the creation and commercialization of drug discovery pipelines through in-house development at King Skyfront, an international strategic base in Tonomachi, Kanagawa Prefecture, where a number of new drug discovery and biotech companies are being establishedRead more…
-
PRESS RELEASE
Metcela and Nagoya University to Collaborate in Research to Accelerate the Development of Regenerative Medicine
Accelerate development of fibroblast-based pipelines in cardiovascular and respiratory disease areasRead more…
-
PRESS RELEASE
Metcela eligible to receive up to $7 Million (1 Billion JPY) AMED Grant for Promoting the Development of Regenerative Medicine Product Using Cardiac Stem Cells
Accelerate the Phase III clinical trial of cardiac stem cell-based product for pediatric congenital heart disease patientsRead more…
-
PRESS RELEASE
Metcela Inc. Completes the Series C Financing of Total $14 Million
Total of $14 million (1.87 billion JPY) was raised in the Series C round, and cumulative $35 million (4.6 billion JPY, including grants) has been raised to date. Metcela is aiming to create new therapeutic options for heart failure by establishing an ecosystem for autologous cell therapy.
-
PRESS RELEASE
Metcela Acquires Japan Regenerative Medicine Co., Ltd., Developing Cardiac Stem Cell-based Therapy
Through this acquisition, Metcela will add an autologous cell product for pediatric congenital heart disease to its pipeline and significantly strengthen its clinical development infrastructure for regenerative medicine products.
-
PRESS RELEASE
Metcela Raises Funds from Two University Venture Capitals
Metcela intends to significantly strengthen its collaboration with Osaka University and Tohoku University in its future development activities through this financing.
